IL118328A - Use of a combination of a forebrain selective N-methyl-D-aspartate antagonist and excitatory feedback enhancing agent in the preparation of pharmaceutical composition for treating Parkinson's disease - Google Patents

Use of a combination of a forebrain selective N-methyl-D-aspartate antagonist and excitatory feedback enhancing agent in the preparation of pharmaceutical composition for treating Parkinson's disease

Info

Publication number
IL118328A
IL118328A IL11832896A IL11832896A IL118328A IL 118328 A IL118328 A IL 118328A IL 11832896 A IL11832896 A IL 11832896A IL 11832896 A IL11832896 A IL 11832896A IL 118328 A IL118328 A IL 118328A
Authority
IL
Israel
Prior art keywords
mmol
pharmaceutical composition
hydroxy
ethyl acetate
hexane
Prior art date
Application number
IL11832896A
Other languages
English (en)
Other versions
IL118328A0 (en
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of IL118328A0 publication Critical patent/IL118328A0/xx
Publication of IL118328A publication Critical patent/IL118328A/en

Links

Classifications

    • G—PHYSICS
    • G10—MUSICAL INSTRUMENTS; ACOUSTICS
    • G10H—ELECTROPHONIC MUSICAL INSTRUMENTS; INSTRUMENTS IN WHICH THE TONES ARE GENERATED BY ELECTROMECHANICAL MEANS OR ELECTRONIC GENERATORS, OR IN WHICH THE TONES ARE SYNTHESISED FROM A DATA STORE
    • G10H5/00—Instruments in which the tones are generated by means of electronic generators
    • G10H5/10—Instruments in which the tones are generated by means of electronic generators using generation of non-sinusoidal basic tones, e.g. saw-tooth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Multimedia (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Acoustics & Sound (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Hydrogenated Pyridines (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
IL11832896A 1995-05-26 1996-05-20 Use of a combination of a forebrain selective N-methyl-D-aspartate antagonist and excitatory feedback enhancing agent in the preparation of pharmaceutical composition for treating Parkinson's disease IL118328A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IB1995/000398 WO1996037226A2 (en) 1995-05-26 1995-05-26 Combinations for the treatment of parkinsonism containing selective nmda antagonists
HU9601419A HUP9601419A3 (en) 1995-05-26 1996-05-24 Synergetic pharmaceutical compositions for treating parkinson-disease

Publications (2)

Publication Number Publication Date
IL118328A0 IL118328A0 (en) 1996-09-12
IL118328A true IL118328A (en) 2001-06-14

Family

ID=89994003

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11832896A IL118328A (en) 1995-05-26 1996-05-20 Use of a combination of a forebrain selective N-methyl-D-aspartate antagonist and excitatory feedback enhancing agent in the preparation of pharmaceutical composition for treating Parkinson's disease

Country Status (26)

Country Link
US (1) US6258827B1 (tr)
EP (1) EP0828513B1 (tr)
JP (1) JPH11505828A (tr)
CN (1) CN1159325A (tr)
AT (1) ATE258067T1 (tr)
AU (1) AU696258B2 (tr)
BR (1) BR9602485A (tr)
CA (1) CA2219911C (tr)
CO (1) CO4700422A1 (tr)
CZ (1) CZ283979B6 (tr)
DE (1) DE69532482T2 (tr)
DK (1) DK0828513T3 (tr)
ES (1) ES2211904T3 (tr)
FI (1) FI974323L (tr)
HU (1) HUP9601419A3 (tr)
IL (1) IL118328A (tr)
MX (1) MX9709112A (tr)
NO (1) NO962130L (tr)
NZ (1) NZ286656A (tr)
PL (1) PL314413A1 (tr)
PT (1) PT828513E (tr)
RU (1) RU2176145C2 (tr)
SG (1) SG45479A1 (tr)
TR (1) TR199600436A2 (tr)
TW (1) TW470740B (tr)
WO (1) WO1996037226A2 (tr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2321190B (en) * 1997-01-16 2000-09-20 Britannia Pharmaceuticals Ltd Pharmaceutical composition
AU760800B2 (en) * 1997-10-24 2003-05-22 Warner-Lambert Company Method for treating disease-related or drug-induced dyskinesias
US6432976B1 (en) 1999-10-29 2002-08-13 Merck & Co., Inc. 8-aza-bicyclo[3.2.1]octane NMDA/NR2B antagonists
US6489477B1 (en) 1999-10-29 2002-12-03 Merck & Co., Inc. 2-aza-bicyclo[2.2.2]octane NMDA/NR2B antigonists
US6380205B1 (en) 1999-10-29 2002-04-30 Merck & Co., Inc. 2-cyclohexyl quinazoline NMDA/NR2B antagonists
US6495561B2 (en) 1999-10-29 2002-12-17 Merck & Co., Inc. 2-cyclohexyl imidazopyridine NMDA/NR2B antagonists
US6476041B1 (en) 1999-10-29 2002-11-05 Merck & Co., Inc. 1,4 substituted piperidinyl NMDA/NR2B antagonists
US6362196B1 (en) 1999-10-29 2002-03-26 Merck & Co., Inc. Method to treat pain utilizing benzimidazole NMDA/NR2B antagonists
US6369076B1 (en) 1999-10-29 2002-04-09 Merck & Co. Inc. 5-benzyl-octahydroindole and 6-benzyl-decahydroquinoline NMDA/NR2B antagonists
US6316474B1 (en) 1999-10-29 2001-11-13 Merck & Co., Inc. 2-benzyl and 2-heteroaryl benzimidazole NMDA/NR2B antagonists
US6291499B1 (en) 1999-10-29 2001-09-18 Merck & Co., Inc. 2-cyclohexyl benzimidazole NMDA/NR2B antagonists
EP1186303A3 (en) * 2000-09-06 2003-12-10 Pfizer Products Inc. Pharmaceutical combinations, for the treatment of stroke and traumatic brain injury, containing a neutrophil inhibiting factor and an selective NMDA-NR2B receptor antagonist
DE60210944T3 (de) 2001-02-23 2015-07-23 Merck Sharp & Dohme Corp. N-substituierte nichtaryl-heterocyclische nmda/nr2b antagonisten
US20020165246A1 (en) * 2001-03-05 2002-11-07 Andrew Holman Administration of sleep restorative agents
AU2002250256B2 (en) 2001-03-08 2008-04-03 Emory University pH-dependent NMDA receptor antagonists
JP2005511478A (ja) 2001-04-03 2005-04-28 メルク　エンド　カムパニー　インコーポレーテッド Ｎ−置換非アリール複素環アミジル系ｎｍｄａ／ｎｒ２ｂ拮抗薬
US20030045449A1 (en) * 2001-08-15 2003-03-06 Pfizer, Inc. Pharmaceutical combinations for the treatment of neurodegenerative diseases
DE10142176A1 (de) * 2001-08-29 2003-03-27 Eucro Europe Contract Res Gmbh Verwendung einer Kombination aus ß-adrenergen Agonisten und NDMA-Antagonisten
WO2003062235A1 (en) * 2002-01-17 2003-07-31 Eli Lilly And Company Modulators of acetylcholine receptors
US6743921B2 (en) * 2002-01-24 2004-06-01 Dsm Catalytica Pharmaceuticals, Inc. Process for the preparation of nonracemic syn-1-(4-hydroxy-phenyl)-2-(4-hydroxy-4-phenyl-piperidin-1-yl)-1-propanol compounds
RU2213565C1 (ru) * 2002-06-24 2003-10-10 Общество с ограниченной ответственностью "Паркинфарм" Способ лечебного воздействия на организм пациента при лечении болезни паркинсона
EP1549314B1 (en) * 2002-10-08 2007-12-12 Allergan, Inc. Use of brimonidine in the treatment of dementia and parkinsons disease
AR044007A1 (es) * 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
US7763588B2 (en) * 2003-06-13 2010-07-27 The Salk Institute For Biological Studies Method for increasing cognitive function and neurogenesis
US20070212345A1 (en) * 2003-09-04 2007-09-13 Ayman Al-Hendy Methods And Compositions For The Prevention And Treatment Of Gentiourinary Disorders Including Pre-Term Labor And Leiomyomas
WO2005025561A1 (en) * 2003-09-04 2005-03-24 Synergia Pharma, Inc. Compositions and methods for orthostatic intolerance
EP1588704A1 (en) 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
US20060240043A1 (en) * 2004-10-08 2006-10-26 Meyerson Laurence R Methods and compositions for treating migraine pain
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
RU2281695C1 (ru) * 2004-12-24 2006-08-20 Дмитрий Владимирович Похабов Способ лечения болезни паркинсона
US7713990B2 (en) * 2005-01-13 2010-05-11 Neurosearch A/S 3,8-substituted 8-AZA-bicyclo[3.2.1]octane derivatives and their use as monomine neurotransmitter re-uptake inhibitors
EP1874282B1 (en) 2005-04-06 2010-09-15 Adamas Pharmaceuticals, Inc. Methods and compositions for treatment of cns disorders
US20070118044A1 (en) * 2005-07-18 2007-05-24 Mega Elektroniikka Oy Method and device for identifying; measuring and analyzing abnormal neurological responses
EP1870097A1 (en) * 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
RU2324492C1 (ru) * 2006-12-04 2008-05-20 Общество с ограниченной ответственностью "Березовый мир" Средство для профилактики и лечения болезни паркинсона
KR20100045983A (ko) * 2007-06-29 2010-05-04 에모리 유니버시티 신경보호를 위한 ｎｍｄａ 수용체 길항물질
RU2393860C2 (ru) * 2008-05-30 2010-07-10 Государственное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко Федерального агентства по здравоохранению и социальному развитию" Использование тизанидина в качестве корректора лекарственного паркинсонизма
RU2540470C9 (ru) * 2008-06-06 2015-07-20 Фарма Ту Б Лтд. Фармацевтические композиции для лечения болезни паркинсона
RU2386458C1 (ru) * 2008-09-04 2010-04-20 Государственное Учреждение Научный Центр Неврологии Российской Академии Медицинских Наук Способ лечения болезни паркинсона
US8648198B2 (en) 2011-01-19 2014-02-11 Cold Spring Harbor Laboratory Phenylethanolamine-based NMDA receptor antagonists
AU2013251079B2 (en) * 2012-04-20 2017-03-23 Ucb Pharma S.A. Methods for treating Parkinson's disease
EP3777833B1 (en) 2014-03-13 2023-10-18 Neuroderm Ltd. Dopa decarboxylase inhibitor compositions
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US12161612B2 (en) 2023-04-14 2024-12-10 Neuroderm, Ltd. Methods and compositions for reducing symptoms of Parkinson's disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5272160A (en) 1989-05-17 1993-12-21 Pfizer Inc 2-piperidino-1-alkanol derivatives as antiischemic agents
MX24433A (es) 1990-02-06 1993-05-01 Pfizer Derivados de 3-piperidino-1-cromanol y sus analogos y procedimiento para su preparacion
CZ390792A3 (en) 1991-04-18 1994-04-13 Pfizer Precursors of medicaments based on esters of phenolic 2-piperidino-1-alkanols, process of their preparation, intermediates and use
DE4118740A1 (de) 1991-06-05 1992-12-10 Schering Ag Neue kombinationspraeparate zur behandlung des morbus parkinson
RU2000114C1 (ru) * 1991-07-18 1993-09-07 Васильев В.Н. Способ Васильева В.Н. лечени заболеваний, св занных с недостаточностью дофаминового обмена

Also Published As

Publication number Publication date
TW470740B (en) 2002-01-01
FI974323A0 (fi) 1997-11-25
EP0828513A2 (en) 1998-03-18
HUP9601419A2 (en) 1997-09-29
HU9601419D0 (en) 1996-07-29
AU5451996A (en) 1996-12-05
WO1996037226A3 (en) 1996-12-27
DE69532482D1 (de) 2004-02-26
NO962130L (no) 1996-11-27
TR199600436A2 (tr) 1996-12-21
CA2219911A1 (en) 1996-11-28
PT828513E (pt) 2004-05-31
WO1996037226A2 (en) 1996-11-28
EP0828513B1 (en) 2004-01-21
NZ286656A (en) 2001-03-30
PL314413A1 (en) 1996-12-09
NO962130D0 (no) 1996-05-24
AU696258B2 (en) 1998-09-03
FI974323A7 (fi) 1997-11-25
FI974323L (fi) 1997-11-25
DK0828513T3 (da) 2004-04-13
CZ283979B6 (cs) 1998-07-15
JPH11505828A (ja) 1999-05-25
BR9602485A (pt) 1998-04-22
ATE258067T1 (de) 2004-02-15
RU2176145C2 (ru) 2001-11-27
SG45479A1 (en) 1998-01-16
DE69532482T2 (de) 2004-11-25
CN1159325A (zh) 1997-09-17
US6258827B1 (en) 2001-07-10
CZ152496A3 (cs) 1998-04-15
MX9709112A (es) 1998-02-28
ES2211904T3 (es) 2004-07-16
HUP9601419A3 (en) 1998-01-28
CA2219911C (en) 2004-07-27
IL118328A0 (en) 1996-09-12
CO4700422A1 (es) 1998-12-29

Similar Documents

Publication Publication Date Title
US6258827B1 (en) Combinations for the treatment of parkinsonism containing selective NMDA antagonists
EP0777652B1 (en) Neuroprotective 3-(piperidinyl-1)-chroman-4,7-diol and 1-(4-hydrophenyl)-2-(piperidinyl-1)-alkanol derivatives
JPS63238054A (ja) フェニルカルバメート
US6958351B2 (en) NMDA NR2B antagonists for treatment
CN101815438A (zh) 治疗依赖性的方法
JPH11504905A (ja) 新規複素環の化学
JPH10502335A (ja) 良性前立腺過形成の治療のためのα−１ｃ特異的化合物の使用
KR101660936B1 (ko) 피질 카테콜아민성 신경전달의 조절자로서의 ３-페닐-３-메톡시피롤리딘 유도체
US20020072485A1 (en) Prophylactic use of N-methyl-D-aspartate (NMDA) antagonists
US20010007872A1 (en) Method of treating acute, chronic and/or neuropathic pain
ES2426915T3 (es) Diastereoisómeros de 4-ariloxi-3-hidroxipiperidinas
JP2007523176A (ja) シタロプラム、エスシタロプラム又はシタロプラム代謝物質を用いる片頭痛又は頭痛疾患の治療又は病気の予防法

Legal Events

Date Code Title Description
FF Patent granted
HK Corrigendum

Free format text: DELETE THE APPLICATION. THE APPLICATION WAS PUBLISHED BY MISTAKE. THE APPLICATION HAS NOT YET BEEN ACCEPTED AND IS NOT OPEN TO THE PUBLIC.

FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees